ESHAP+fixed dose G-CSF as autologous peripheral blood stem cell mobilization regimen in patients with relapsed or refractory diffuse large cell and Hodgkin's lymphoma: a single institution result of 127 patients

Akhtar, Saad; Tbakhi, Abdelghani; Humaidan, Hind Al; Weshi, Amr El; Rahal, M.; Maghfoor, Irfan

doi:10.1038/sj.bmt.1705239

Cited by 30 publications

(20 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In the majority of previous reports on high-dose chemotherapy, data on CD34 + cell mobilization are lacking and details on PBSC mobilization and collection are reported in a limited number of studies 11,23,[30][31][32] (Table 6). An adequate stem cell collection (>2×10 6 CD34 + cells/kg) was observed in over 80% of patients.…”

Section: Discussionmentioning

confidence: 99%

Ifosfamide, gemcitabine, and vinorelbine: a new induction regimen for refractory and relapsed Hodgkin's lymphoma

Santoro¹,

Magagnoli²,

Spina³

et al. 2007

Haematologica

214

140

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Ifosfamide, gemcitabine, and vinorelbine: a new induction regimen for refractory and relapsed Hodgkin's lymphoma

Santoro¹,

Magagnoli²,

Spina³

et al. 2007

Haematologica

214

140

View full text Add to dashboard Cite

“…Limited data is available for ESHAP chemotherapy as a mobiliser. Few available studies had shown that ESHAP can be used safely as a mobiliser regimen [10,11,13,15]. Very little is reported about the factors affecting CD34þ cells collection in patients receiving ESHAP.…”

Section: Introductionmentioning

confidence: 94%

Factors affecting autologous peripheral blood stem cell collection in patients with relapsed or refractory diffuse large cell lymphoma and Hodgkin lymphoma: A single institution result of 168 patients

Akhtar

Weshi

Rahal

et al. 2008

Leukemia & Lymphoma

View full text Add to dashboard Cite

From 1996 to April 2006, 174 consecutive patients with relapsed or refractory diffuse large cell lymphoma (DLCL) and Hodgkin lymphoma (HL) received ESHAP as salvage and for mobilisation. Males 92, females 76. DLCL 64: HL 104, prior radiation in 35%. First relapse 45%, second relapse 12%, induction failure 43%. Median prior chemotherapy cycles were 6. Median age at apheresis was 26.5 years. Six patients failed mobilisation and 21 patients had CD34+ cells collection < 2 x 10(6)/kg on first apheresis. Median CD34+ cells/kg collection was 5.5 x 10(6)/kg for first apheresis and 6.7 x 10(6)/kg for all apheresis. We evaluated impact of histology, gender, age, stage, marrow involvement, prior radiation and chemotherapy cycles, timing (relapse1: relapse > 1: refractory), platelet count and weight. For first apheresis collection; all patients, younger age (p = 0.004), for DLCL (64), younger age (p = 0.021) and higher platelet count (p = 0.013) and for HL (104), younger age (p = 0.036) and male gender had better CD34+ cells collection. For all apheresis product, for all patients, age (p = 0.001) and no prior radiation therapy (p = 0.051) had better CD34+ cells collection. Higher first harvest CD34+ cells collection also resulted in early neutrophil (p < or = 0.001) and platelet (p = 0.004) engraftment.

show abstract

“…Fifty-three (91%) patients had ESHAP þ G-CSF as mobilization regimen for PBSC. 28 Two (4%) patient had cytoxan and G-CSF for mobilization. One patient failed both ESHAP and then cytoxan and G-CSF mobilization, and required BM harvest.…”

Section: Patient Characteristics Are Shown Inmentioning

confidence: 99%

High-dose chemotherapy and autologous stem cell transplant in adolescent patients with relapsed or refractory Hodgkin's lymphoma

Akhtar

Weshi

Rahal

et al. 2009

Bone Marrow Transplant

Self Cite

View full text Add to dashboard Cite

ESHAP+fixed dose G-CSF as autologous peripheral blood stem cell mobilization regimen in patients with relapsed or refractory diffuse large cell and Hodgkin's lymphoma: a single institution result of 127 patients

Cited by 30 publications

References 32 publications

Ifosfamide, gemcitabine, and vinorelbine: a new induction regimen for refractory and relapsed Hodgkin's lymphoma

Ifosfamide, gemcitabine, and vinorelbine: a new induction regimen for refractory and relapsed Hodgkin's lymphoma

Factors affecting autologous peripheral blood stem cell collection in patients with relapsed or refractory diffuse large cell lymphoma and Hodgkin lymphoma: A single institution result of 168 patients

High-dose chemotherapy and autologous stem cell transplant in adolescent patients with relapsed or refractory Hodgkin's lymphoma

Contact Info

Product

Resources

About